Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-22
2007-05-22
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S122000
Reexamination Certificate
active
10854959
ABSTRACT:
A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
REFERENCES:
patent: 6750237 (2004-06-01), Dearn et al.
patent: 0 636 623 (1995-02-01), None
patent: 636623 (1995-02-01), None
patent: 2 315 673 (1998-02-01), None
patent: WO 98/02187 (1998-01-01), None
patent: WO-9802186 (1998-01-01), None
patent: WO 9802186 (1998-01-01), None
patent: WO-98/34595 (1998-08-01), None
patent: WO 98/34595 (1998-08-01), None
Coomber Trevor John
Dearn Alan Roy
Summers John Simon
Williamson Sarah Louise
AstraZeneca AB
Kondrad Karen H.
Pryor Alton
LandOfFree
Pharmaceutical formulations containing zolmitriptan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations containing zolmitriptan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations containing zolmitriptan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751709